Ozempic, Wegovy linked to rare cases of eye disorder, EMA says By Staff Reuters Posted June 6, 2025 8:21 am 1 min read ...

GLP-1 drugs, such as semaglutide (sold under brand names like Ozempic and Wegovy), are a class of medications that mimic a hormone called glucagon-like peptide-1 (GLP-1).

Novo Nordisk has launched Wegovy in India, a weight-loss drug challenging Eli Lilly's Mounjaro. Available by June 2025, ...

Check out the “How to use the Wegovy pen” video on the manufacturer’s website. Follow the step-by-step directions outlined in the drug’s prescribing information (beginning on page 38).

Higher doses (25 mg, 50 mg) have been studied for weight loss and may offer similar results to the Wegovy 2.4 mg dose. But it’s important to note that oral semaglutide isn’t absorbed as well ...

Novo Nordisk has launched Wegovy, a weight loss injection, in India, challenging Eli Lilly's Mounjaro. Available by June 2025 ...

People can only get Wegovy online with a doctor’s prescription. Eligible people must meet specific eligibility criteria, including having a body mass index (BMI) of 30 or higher or a BMI of 27 ...

Novo Nordisk’s arch-rival in the obesity market is Eli Lilly LLY. NVO’s Ozempic and Wegovy face strong competition from Lilly’s tirzepatide medicines, Mounjaro (T2D) and Wegovy (obesity).

Results from the phase 3b STEP UP trial showed that a higher dose of Wegovy® (semaglutide 7.2 mg) delivered 21% weight loss in people with obesity, with a third of participants losing 25% or more ...

The European Medicines Agency's (EMA) safety committee (PRAC) has concluded its review of medicines containing semaglutide following concerns regarding a possible increased risk of developing non ...

Wegovy (semaglutide) is a prescription drug used for weight loss and to reduce the risk of serious cardiovascular issues. Wegovy can interact with some supplements and other medications, such as ...

Higher dose of Wegovy® provided average weight loss of 21% in people with obesity - with a third achieving 25% or more - according to data presented at ADA Results from the phase 3b STEP UP trial ...